Us Alzheimers Linked Imaging Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The Alzheimer's-linked imaging market in the United States covers the full spectrum of neuroimaging modalities applied to dementia care, including amyloid PET, tau PET, structural MRI, functional MRI, and CT scanning. In 2024, the U.S. market was valued at approximately $4.49 billion, with estimates placing it near $4.96 billion by 2026 and on track to reach roughly $6.90 billion by 2033, reflecting a 5.1% annual growth rate over the forecast horizon. The market sits within the broader Alzheimer's disease diagnostics sector, which is expanding at a significantly faster pace of roughly 10.6% CAGR through 2030, indicating that imaging constitutes one of several high-growth diagnostic categories.

• •Market valued at ~$4.49B in 2024, projected to reach ~$6.90B by 2033 at a 5.1% CAGR
• •Covers amyloid PET, tau PET, MRI, and CT imaging modalities used in Alzheimer's diagnosis and monitoring
• •Estimated near $4.96B by 2026, placing it on solid growth trajectory through the decade

The primary engine of market expansion is the escalating prevalence of Alzheimer's disease driven by the aging U.S. demographic, which is steadily increasing the pool of patients requiring diagnostic evaluation. Broader reimbursement coverage for advanced imaging modalities, combined with growing clinical acceptance of amyloid and tau PET tracers, is removing barriers to adoption among physicians and patients alike. Meanwhile, memory care centers and diagnostic facilities are actively expanding their imaging infrastructure to meet rising demand, further accelerating utilization rates across the country.

• •Rising prevalence of Alzheimer's disease tied to aging U.S. population expands patient base for diagnostic imaging
• •Expanding reimbursement and clinical validation for amyloid PET and tau imaging improve accessibility
• •Memory care centers and imaging facilities investing in new equipment to capture growing patient demand

The market can be broadly segmented by imaging modality, with amyloid PET and structural MRI representing the dominant categories, followed by tau PET and functional neuroimaging techniques used in research and specialty clinical settings. End-use segments include hospitals and diagnostic imaging centers, specialty neurology and memory clinics, and academic or research institutions conducting clinical trials for novel Alzheimer's therapeutics. Geographically, the U.S. dominates the North American landscape due to advanced healthcare infrastructure, high disease prevalence, and widespread insurance coverage, though regional variation exists with urban academic medical centers generally leading in advanced imaging adoption.

• •Modality segments dominated by amyloid PET and structural MRI, with tau PET emerging as a fast-growing subcategory
• •End-use split across hospital systems, specialty memory clinics, and academic research institutions
• •U.S. drives the North American market, with urban academic centers showing the highest adoption of advanced imaging technologies

Who are the notable companies in the industry?

The competitive structure is characterized by moderate consolidation, with a handful of large, diversified healthcare technology and pharmaceutical companies competing alongside a tier of smaller specialty firms focused exclusively on neuroimaging agents and diagnostic services. A significant portion of the market is vertically integrated, where major radiology equipment manufacturers also develop or license companion imaging tracers and software platforms that bundle hardware and consumables. Siemens Healthineers leverages its PET-MR hybrid platforms to dominate high-end hospital deployments, while GE HealthCare anchors its position through cyclotron networks that secure radiotracer supply chains across major metropolitan hubs. Fujirebio competes in the cerebrospinal fluid biomarker segment, offering laboratories an alternative to capital-intensive imaging infrastructure. The primary technology routes revolve around PET radiotracer chemistry for amyloid and tau detection and high-field MRI systems optimized for structural and functional brain imaging, with capacity concentrated at major diagnostic and pharmaceutical manufacturing hubs in the United States.

• •Moderate market consolidation with integrated producers controlling significant share alongside niche specialty participants
• •Core technology routes: PET radiotracer production (amyloid and tau) and MRI system manufacturing and service
• •Manufacturing and advanced imaging capacity concentrated in major U.S. healthcare and industrial regions

What are the recent trends and outlook?

The market is positioned for sustained growth through 2033, supported by ongoing pipeline development of next-generation imaging tracers that promise higher specificity and lower scan times, as well as the progressive integration of artificial intelligence tools that assist in interpreting complex brain scan data. As disease-modifying therapies for Alzheimer's gain regulatory approval, imaging will become increasingly essential for patient selection, treatment monitoring, and clinical endpoint measurement in drug development. This therapeutic-imaging convergence is expected to elevate the strategic importance of the sector and sustain above-average investment across both diagnostic infrastructure and biomarker development through the forecast period.

• •Next-generation PET tracers and AI-assisted image interpretation tools expected to drive adoption and improve diagnostic precision
• •Disease-modifying Alzheimer's therapies will increasingly rely on imaging for patient stratification and treatment monitoring
• •Therapeutic-imaging convergence likely to attract sustained investment and reinforce long-term market growth above 5% annually